S-pindolol benzoate (ACM-001.1)

S-pindolol has been described as an anabolic/catabolic transforming agent, or ACTA1. A clinical development programme for our new salt of S-pindolol, S-pindolol benzoate (ACM-001.1), is underway. A Pharmacokinetic and Pharmacodynamic (PK/PD) study (NCT06028321) was completed in 2022. 

Following this successful PK/PD study, a Phase 2b/3 clinical development programme, the IMPACT Programme (Improving cancer cachexia with ACTAs), is in planning to confirm and expand upon the positive results demonstrated in an exploratory proof of concept Phase 2a trial for S-pindolol, (ACT-ONE2).

The IMPACT Programme will consist of two trials with identical design: one in patients with non-small cell lung cancer (NSCLC) and the other in colorectal cancer (CRC), both groups with a diagnosis of cachexia. The studies will respectively be designated IMPACT-NSCLC and IMPACT-CRC.

Actimed received FDA approval of its Investigational New Drug (IND) application for the IMPACT Programme in August 2023. The Company plans to dose the first patients in 2025.

 

Mode of action

S-pindolol (ACM-001) is an anabolic/catabolic transforming agent with a multifunctional effect on three key pharmacological targets relevant for cancer cachexia:

•  Reduction of catabolism by β-1 receptor antagonism3,4,5

•  Increased anabolism and muscle growth, through partial β2 receptor agonism1

•  Improvement in appetite and fatigue via central 5-HT1a antagonism6,7,8,9,10,11

This trio of anti-catabolic and pro-anabolic pharmacology makes S-pindolol benzoate (ACM-001.1) a highly promising candidate for development in cancer cachexia.

 

 

Jun 23, 2022
Actimed Therapeutics to present on development of its lead asset in treatment of cancer cachexia at the Society on Sarcopenia, Cachexia and Wasting Disorders

London, UK – 23 June 2022. Actimed Therapeutics Ltd, the clinical stage company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders announces that its Chief Medical Officer, Frank Misselwitz MD PhD, will present on the clinical development of its lead candidate S-pindolol benzoate at the 15th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Lisbon, Portugal. In addition, he will present conference highlights on the treatment of cancer cachexia and co-chair a session on inter-organ cross-talks in cancer cachexia.

The Company’s co-founder Stefan Anker will also co-chair the conference’s opening session. The presentations will take place both virtually and in Lisbon across 25 - 26 June 2022 and can be viewed live via this link: https://bit.ly/3y9kBcn 

Details for each session are as follows:

Saturday 25 June

Session:                       Opening Session

Time:                           10:00 - 11:00 WEST

 

Clinical Session:           Inter-organ cross talks in cancer cachexia 

Time:                           10:00 - 10:45 WEST                

            

Sunday 26 June

Session:                       Late Breaking Trials

Title:                            Use of chirally pure S-enantiomers in the treatment of cancer cachexia: Clinical Development of S-pindolol benzoate in cancer cachexia in patients with advanced Non-Small Cell Lung and Colo-Rectal Cancer

Time:                           13:00 - 13:50 WEST

 

Session:                       Conference Highlights

Title:                            Treatment of Cancer Cachexia 

Time:                           15:00 - 15.50 WEST

 

About Actimed Therapeutics  

Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicians in muscle wasting research.  

The lead area of focus for Actimed is specifically in cachexia. Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia.  

It has been estimated that cachexia affects 50–80% of cancer patients and accounts for up to 20% of cancer deaths. Treating cancer cachexia successfully may increase both the length and quality of life for cancer patients.  

The lead product of Actimed, S-pindolol benzoate (ACM-001.1) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase II clinical data in cachexia patients. Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).  

Actimed has also licensed the global rights to develop and commercialise S-oxprenolol, for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS) to Faraday Pharmaceuticals. Actimed retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting may impact survival.

 

About SCWD

SCWD is a non-profit scientific organization comprised of an international and multidisciplinary group of health-care professionals primarily active in these fields that seeks to further research on cachexia and sarcopenia and wasting disorders and bring practical solutions to health-care teams worldwide grappling with treatment.

SCWD was founded to improve patient health worldwide and to encourage prevention and treatment of these conditions. The spectrum of clinical disorders represented by the SCWD Society includes, but is not limited to cachexia, sarcopenia, the syndrome of muscle wasting associated to cancer, COPD, diabetes, heart failure, HIV/ Aids, malnutrition, aging and other chronic conditions.

Back